Indivior (LON:INDV)‘s stock had its “buy” rating reiterated by equities researchers at Jefferies Group in a research report issued on Wednesday. They currently have a GBX 500 ($6.78) price objective on the specialty pharmaceutical company’s stock. Jefferies Group’s price target would indicate a potential upside of 24.69% from the stock’s previous close.
INDV has been the topic of a number of other reports. Numis Securities restated a “buy” rating and set a GBX 640 ($8.68) price target on shares of Indivior in a research report on Thursday, November 30th. Royal Bank of Canada restated an “outperform” rating and set a GBX 500 ($6.78) price target on shares of Indivior in a research report on Friday, December 1st. Citigroup restated a “neutral” rating and set a GBX 280 ($3.80) price target on shares of Indivior in a research report on Thursday, October 26th. Finally, Morgan Stanley increased their price target on Indivior from GBX 320 ($4.34) to GBX 410 ($5.56) and gave the stock an “equal weight” rating in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Indivior currently has an average rating of “Buy” and an average target price of GBX 476.43 ($6.46).
Indivior (LON INDV) traded up GBX 4 ($0.05) during midday trading on Wednesday, reaching GBX 401 ($5.44). The company had a trading volume of 915,229 shares, compared to its average volume of 1,480,000. The company has a market cap of $2,890.00 and a price-to-earnings ratio of 1,542.31. Indivior has a 1-year low of GBX 246.50 ($3.34) and a 1-year high of GBX 421.50 ($5.72).
COPYRIGHT VIOLATION WARNING: “Jefferies Group Reiterates “Buy” Rating for Indivior (INDV)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/19/jefferies-group-reiterates-buy-rating-for-indivior-indv.html.
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.